The Connecticut State Legislature has introduced Senate Bill 11, aimed at addressing the rising costs of prescription drugs in the state. The bill, presented on April 2, 2025, proposes a comprehensive study to explore the feasibility of establishing a Canadian prescription drug importation program. This initiative seeks to provide residents with more affordable medication options by potentially allowing the importation of drugs from Canada, where prices are often significantly lower.

Key provisions of the bill include the hiring of a consultant by the Commissioner of Consumer Protection to conduct the feasibility study. This study is expected to be completed by October 1, 2027, at which point the Commissioner will report findings to relevant legislative committees. If the study concludes that a Canadian importation program is viable, the Commissioner may then seek approval from the federal Food and Drug Administration (FDA) to implement the program.

The introduction of Senate Bill 11 has sparked notable discussions among lawmakers and stakeholders. Proponents argue that the bill could lead to substantial savings for consumers and alleviate the financial burden of high prescription drug prices. However, there are concerns regarding the safety and regulatory implications of importing drugs from abroad. Critics worry about the potential risks associated with drug quality and the complexities of navigating federal regulations.

The economic implications of the bill are significant, as high prescription drug costs have been a persistent issue affecting many Connecticut residents. By potentially lowering these costs, the bill could improve access to necessary medications and enhance public health outcomes. Additionally, the bill reflects a growing trend among states to seek innovative solutions to combat rising healthcare expenses.

As the bill progresses through the legislative process, its future remains uncertain. The outcome of the feasibility study will be crucial in determining whether Connecticut will move forward with a Canadian prescription drug importation program. If successful, this initiative could serve as a model for other states grappling with similar challenges in healthcare affordability.